2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patients
2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease